



Mr. Jialin Zhang

CFA, CPA, *Head of Healthcare & Pharmaceuticals*

张佳林先生

野村中国香港医药研究部主管

Jialin has 10 years of experience leading a China/HK healthcare equity research franchise. In the 2023 II All-Asia Survey, he ranked as Runner-up in China Healthcare

Jialin connects well with the China healthcare community (corporates, entrepreneurs, investors, doctors, professors, and reporters). He runs various events including corporate NDRs, physical tours, and expert calls.

In 2024, Jialin published four Anchor Reports and approximately 240 short reports that provided both in-depth analysis of several China healthcare subsectors and prompt responses on leading corporates' updates.

He covers 40 stocks along the value chain from pharma, biotech, CRO, medical devices, healthcare services, distributors, pharmacies, and consumer health companies, among which, his sector pecking order is medical devices, biotech, pharmaceuticals, pharmacies, distributors, CROs and hospitals. Snibe, Mindray, Beigene, Yifeng and Wuxi XDC are Jialin's top picks.